Island Pharmaceuticals
Island Pharmaceuticals is an Australian clinical-stage antiviral biotech (ASX: ILA) repurposing small-molecule drugs for dengue fever (ISLA-101) and developing Galidesivir for Marburg virus under the FDA Animal Rule pathway for US biodefense procurement.
- Company typePublic
- Founded2021
- HeadquartersCamberwell, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Island Pharmaceuticals does
Island Pharmaceuticals Limited (ASX: ILA) is a clinical-stage Australian antiviral therapeutics company that develops and repurposes small-molecule drugs for infectious diseases with limited or no approved treatment options. The company is headquartered in Camberwell, Victoria, and has operated with a headcount of 1-10 employees since its oversubscribed IPO on the Australian Securities Exchange in April 2021.
The company's pipeline comprises two core assets. ISLA-101 is an antiviral compound being repurposed for dengue fever and other mosquito-borne flavivirus infections, supported by patents granted in the US, Australia, Canada, and Brazil (with US IP extending through 2042 for COVID-19 use), and has progressed through a successful Phase 2a readout and Phase 2b enrollment. Galidesivir was acquired from BioCryst in July 2025 and is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway, with FDA Orphan Drug Designation and Tropical Disease Priority Review Voucher eligibility confirmed; a three-year CRADA with USAMRIID and The Geneva Foundation, plus a Master Service Agreement with Texas Biomedical Research Institute for BSL-4 non-human primate studies, support the development program.
Island is pre-revenue and does not yet commercialize any product. Its go-to-market model is dual-track: an endemic commercial path for ISLA-101 through standard pharmaceutical development and regulatory approval, and a US government biodefense procurement path for Galidesivir targeting the Department of Defense and Health and Human Services, with Priority Review Voucher monetization as an additional value lever. Revenue mechanics are therefore expected to combine eventual product sales, government stockpiling contracts, and potential licensing or PRV transactions. Capital is sourced primarily through ASX-listed equity placements, rights issues, and a US government grant, with a stated A$9 million placement in February 2026 explicitly dedicated to financing the Galidesivir program.
Island Pharmaceuticals firmographics
Firmographics- Name
- Island Pharmaceuticals
- Legal name
- Island Pharmaceuticals Limited
- Website
- https://islandpharmaceuticals.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Island Pharmaceuticals is an Australian clinical-stage antiviral biotech (ASX: ILA) repurposing small-molecule drugs for dengue fever (ISLA-101) and developing Galidesivir for Marburg virus under the FDA Animal Rule pathway for US biodefense procurement.
- Ownership category
- akta.pro rank
Island Pharmaceuticals industry classification
Industry- Product category
- Antiviral Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Island Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Camberwell
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Island Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Island Pharmaceuticals is a clinical-stage biotech company that does not yet have commercialized products. The company is developing ISLA-101 for dengue fever and Galidesivir for Marburg virus. Revenue will come from product sales pending regulatory approvals.
- Government Procurement: The company targets US government procurement and stockpiling of Galidesivir as a biodefense countermeasure, with potential Priority Review Voucher eligibility upon approval.
- Priority Review Voucher: Upon FDA approval of Galidesivir for tropical diseases like Marburg virus, the company may be eligible for a Tropical Disease Priority Review Voucher which can be sold to other pharmaceutical companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Island Pharmaceuticals product offering
Product offeringCore offering
Island Pharmaceuticals is a clinical-stage antiviral therapeutics company developing and repurposing drug candidates for infectious diseases. Its lead asset ISLA-101 is being developed as a treatment for dengue fever and other mosquito-borne flavivirus infections, while Galidesivir is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway for biodefense applications.
Product overview
Island Pharmaceuticals is an antiviral therapeutics company with two core drug candidates: ISLA-101 and Galidesivir. ISLA-101 is being developed for dengue fever and other mosquito-borne diseases (flaviviruses), having successfully completed Phase 2a trials. Galidesivir is being developed for biodefense applications targeting Marburg virus under FDA Animal Rule pathway. The company focuses on drug repurposing strategies to accelerate development of treatments for unmet needs in infectious diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- ISLA-101
Quantifiable outcome
- Phase 2a clinical trial achieved endpoints in dengue fever patients
- +2 more outcomes
Companies that use Island Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles2 records
Island Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Island Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and supporting.
- USAMRIID (United States Army Medical Research Institute of Infectious Diseases)coreThree-year Cooperative Research and Development Agreement (CRADA) with USAMRIID and The Geneva Foundation to advance Galidesivir for Marburg Virus Disease under the FDA Animal Rule pathway. Non-human primate studies are planned as key steps toward New Drug Application approval.
- The Geneva FoundationcorePartnering with USAMRIID under the three-year CRADA to advance Galidesivir development. The Geneva Foundation supports military medical research and provides access to specialized research capabilities.
- Texas Biomedical Research InstitutecoreMaster Service Agreement with Texas Biomedical for antiviral drug development. Texas Biomed provides BSL-4 (Biosafety Level 4) laboratory capabilities for non-human primate studies required for Galidesivir development under the FDA Animal Rule pathway.
- Medical Countermeasures CoalitionmajorIsland Pharmaceuticals joined the Medical Countermeasures Coalition, which advances US government procurement and stockpiling of medical countermeasures. Coalition membership supports the company's pathway to potential US government procurement for Galidesivir.
- Galidesivir Acquisition from BioCrystcoreIsland Pharmaceuticals completed the acquisition of Galidesivir from BioCryst, expanding its antiviral portfolio. This transaction brought the Marburg virus asset into Island's pipeline.
- Washington-based Policy AdvisorsupportingAppointed a Washington-based policy advisor to advance US government engagement and navigate regulatory pathways for the Galidesivir biodefense program.
- Griffith UniversitysupportingAnti-Viral Molecule Screening Collaboration with Griffith University for screening of antiviral compounds.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Island Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Bavarian Nordic: European biodefense and infectious disease vaccine/antiviral company with FDA-approved JYNNEOS smallpox vaccine and significant BARDA contracts. Larger established player in the same medical countermeasures space Island is targeting with Galidesivir.
- Moderna: Developing mRNA-based dengue vaccine candidates through Phase 3 trials and has broad infectious disease vaccine capabilities. Represents the competitive vaccine landscape that ISLA-101 (an antiviral) would need to complement or compete against.
- Novavax: Vaccine developer with approved products for COVID-19 and R21/Matrix-M malaria vaccine (dengue-adjacent). Larger infectious disease vaccine player that overlaps with the flavivirus therapeutic and biodefense space where Island operates.
- Emergent BioSolutions: Larger biodefense and specialty pharma incumbent that supplies medical countermeasures to US government (anthrax vaccines, smallpox, NARCAN). Comparable business model of pursuing FDA Animal Rule approvals and government procurement contracts, though at much greater scale.
- Takeda Pharmaceutical: Owns QDENGA, the leading approved dengue vaccine, and has deep dengue commercial infrastructure across endemic regions. While not a direct antiviral peer, Takeda represents the dominant commercial competitor for any dengue therapeutic seeking market access.
Emerging players
- Atea Pharmaceuticals: Clinical-stage antiviral developer that has historically pursued dengue and other flavivirus therapeutics, providing a direct comparable in the dengue antiviral development pathway that Island is following with ISLA-101.
- Arcturus Therapeutics: Clinical-stage biotech with dengue vaccine (Phase 2) and self-amplifying mRNA platform. Similar profile to Island as a small-cap antiviral/infectious disease developer targeting dengue with regulatory pathway validation.
Direct peers
- BioCryst Pharmaceuticals: Originally developed Galidesivir before divesting it to Island Pharmaceuticals. BioCryst is a US clinical/commercial antiviral company focused on rare disease antivirals (Rapivab, Orladeyo), making it the most direct prior owner and developer of Island's lead biodefense asset.
- Chimerix: Small-cap US antiviral company focused on rare/orphan infectious diseases, including work on filoviruses and biodefense indications. Direct comparable in size, clinical-stage profile, and antiviral pipeline focus.
- SIGA Technologies: US biodefense-focused pharma with TPOXX (tecovirimat) approved for smallpox via the FDA Animal Rule. Direct comparable for Island's Galidesivir strategy of pursuing Animal Rule approval for filovirus/orthopoxvirus countermeasures with US government stockpiling.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Island Pharmaceuticals social profiles
Digital presenceIsland Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Island Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Island Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Island Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Island Pharmaceuticals
What does Island Pharmaceuticals do?
Island Pharmaceuticals is a clinical-stage antiviral therapeutics company developing and repurposing drug candidates for infectious diseases. Its lead asset ISLA-101 is being developed as a treatment for dengue fever and other mosquito-borne flavivirus infections, while Galidesivir is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway for biodefense applications.
Is Island Pharmaceuticals a public or private company?
Island Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Island Pharmaceuticals founded?
Island Pharmaceuticals was founded in 2021. It employs 1 to 10 people.
Where is Island Pharmaceuticals based?
Island Pharmaceuticals is headquartered in Camberwell, Australia, in the Oceania region.
How does Island Pharmaceuticals make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are government Procurement and priority Review Voucher.
Who are Island Pharmaceuticals's main competitors?
Broad incumbents on record are Bavarian Nordic, Moderna, Novavax, Emergent BioSolutions and Takeda Pharmaceutical. Emerging players are Atea Pharmaceuticals and Arcturus Therapeutics. Direct peers are BioCryst Pharmaceuticals, Chimerix and SIGA Technologies.
Does Island Pharmaceuticals have an API?
No public API is recorded for Island Pharmaceuticals.
What industry is Island Pharmaceuticals in?
Island Pharmaceuticals's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.